Abstracts Archive - Page 412 of 2425 - ACR Meeting Abstracts

Abstract Number: 2124 • ACR Convergence 2022
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
Stefan Siebert¹, Laura Coates², Georg Schett³, Siba P. Raychaudhuri⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷, Frederic Lavie⁸, Elke Theander⁹, Marlies Neuhold¹⁰, Alexa Kollmeier¹¹, Xie L Xu¹², Proton Rahman¹³, Philip J Mease¹⁴ and Atul Deodhar¹⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ⁹Janssen Cilag, Lund, Sweden, ¹⁰Janssen, Zug, Switzerland, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹³Memorial University, St. John's, NL, Canada, ¹⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹⁵Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate…
Abstract Number: 1967 • ACR Convergence 2022
Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², orit schieir², Louis Bessette³, Gilles Boire⁴, Susan Bartlett⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰ and Vivian Bykerk¹¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Early work cessation and reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We…
Abstract Number: 2130 • ACR Convergence 2022
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
Petros P. Sfikakis¹, Dimitrios Vassilopoulos², Gkikas Katsifis³, Georgios Vosvotekas⁴, Theodoros Dimitroulas⁵, Argyro Repa⁶, Grigorios Sakellariou⁷, THEODORA SIMOPOULOU⁸, Athanasios Georgountzos⁹, Andreas Bounas¹⁰, Panagiotis Georgiou¹¹, Evangelia Mole¹², Evangelia Kataxaki¹³, Stamatis Nick Liossis¹⁴, Evangelos Theodorou¹⁵, Christina Antoniadou¹⁶, EVANGELOS THEOTIKOS¹⁷, PANAYIOTIS VLACHOYIANNOPOULOS¹⁸, THEODORA MARKATSELI¹⁹, Angeliki Kekki²⁰, NIKOLAOS ANTONAKOPOULOS²¹ and Dimitrios Boumpas²², ¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ³Naval Hospital of Athens, Athens, Greece, ⁴Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁵4th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁶Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, ⁷Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, ⁸Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, ⁹General Hospital of Athens G. Gennimatas, Athens, Greece, ¹⁰Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, ¹¹Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, ¹²Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, ¹³Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, ¹⁴Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, ¹⁵Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, ¹⁶First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ¹⁷Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, ¹⁸Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²⁰Genesis Pharma SA, Halandri, Greece, ²¹Genesis Pharma SA, Chalandri, Greece, ²²4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2117 • ACR Convergence 2022
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J Mease¹, Laura Coates², Robert Landewé³, Iain B McInnes⁴, Christopher Ritchlin⁵, Tatsuya Atsumi⁶, Frank Behrens⁷, Dafna Gladman⁸, Laure Gossec⁹, Peter Nash¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Jason Coarse¹², Adam R Prickett¹³ and Alice Gottlieb¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Amsterdam University Medical Center, Meerssen, Netherlands, ⁴Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Hokkaido University, Sapporo, Japan, ⁷Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁹Sorbonne Université, Paris, France, ¹⁰School of Medicine, Griffith University, Sunshine Coast, Australia, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹³UCB Pharma, Brussels, Belgium, ¹⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Tala El Tal¹, Santiago Arciniegas², Sarah Mossad³, Ibrahim Mohamed⁴, Victoria Lishak⁵, Stephanie Fevrier⁶, Lawrence Ng³, Paris Moaf³, Joanna Law³, ashley Danguecan³, Linda Hiraki⁷, Deborah Levy⁸ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁵The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2077 • ACR Convergence 2022
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Background: Early complete remission (within 12 months from diagnosis) is considered an important protective factor against development of advanced chronic kidney disease (CKD) in…
Abstract Number: 1965 • ACR Convergence 2022
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
Hsin-Yi Peng¹, Ting-Yin Xue¹, Fei-Hung Hsieh¹, Yi-Ko Chen¹, Mei-Chin Yin², Che-Yi Chao², Shu-Yao Tsai², Chung-Ping Lin³, Po-Hao Huang³, Chien-Chung Huang³, Jiunn-Horng Chen³, Chung-Ming Huang³, Der-Yuan Chen⁴, Joung-Liang Lan⁵ and Gregory Tsay³, ¹China Medical University, Taichung, Taiwan, ²Asia University, Taichung, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, ⁵China Medoical University Hospital, Taichung, Taiwan
Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
Abstract Number: 2128 • ACR Convergence 2022
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
Iain B McInnes¹, John Tesser², Elena Schiopu³, Joseph Merola⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, Natalie Shiff⁷, Alexa Kollmeier⁸, Xie L Xu⁹, May Shawi¹⁰, Frederic Lavie¹¹, Paul Bird¹² and Philip J Mease¹³, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁹Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹⁰Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹¹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ¹²University of New South Wales, Sydney, Australia, ¹³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: In the phase 3 DISCOVER (D)-1 and D-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of…
Abstract Number: 2085 • ACR Convergence 2022
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
Abstract Number: 2021 • ACR Convergence 2022
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
Xiaomei Shan¹, Clara Reichardt¹, Jeeshan Singh¹, Anne Zeitler², Christine Schauer¹, Jasmin Knopf¹, Martin Herrmann¹, Gerhard Grossmayer¹, Georg Schett¹ and Luis Munoz¹, ¹Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
Abstract Number: 1878 • ACR Convergence 2022
Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
Haruna Matsuo¹, Toshimasa Shimizu¹, Tomohiro Koga¹, Nozomi Oki², Masataka Uetani² and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Muscle inflammation is a major clinical manifestation in patients with polymyositis/dermatomyositis (PM/DM). Phenotypes of PM/DM patients, especially those with interstitial lung diseases, are known…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].